Researchers from the George Washington University (GW) Cancer Center recently participated in the American Society of Clinical Oncology (ASCO) Annual Meeting held June 1-5, 2018 in Chicago. At the meeting, Robert Siegel, MD, associate center director for education and training at the GW Cancer Center, gave an oral presentation on the results of a Phase II study, "Induction chemotherapy and transoral surgery as definitive treatment for locally advanced oropharyngeal squamous cell carcinoma: A novel approach." Associate center director for translational research and innovation at the GW Cancer Center, Cath Bollard, MD, also presented on "The landscape of anti-CD-19 CAR-T cells in the management of Non-Hodgkin Lymphoma." Read more about the GW Cancer Center at ASCO 2018 below.
GW Cancer Center researchers presented the following sessions and articles:
A prospective study of pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN0321.
Geller, J.I., Cost, N.G., Chi, Y.Y., Perlman, E.J., Kim, Y., Cajaiba, M., Mullen, E.A., Glick, R.D., Khanna, G., Daw, N.C., Ehrlich, P.F., Fernandez, C.V., Dome, J.
Oral Session: #10516 Pediatric Oncology II
Favorable outcomes can be achieved without adjuvant therapy in children and adolescents with completely resected RCC, including those with locally advanced disease and lymph node involvement. (Read more)
Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival
Peereboom, D.M., Nabors, L.B., Kumthekar, P., Badruddoja, M.A., Fink, K.L., Lieberman, F.S., Phuphanich, S., Dunbar, E.M., Walbert, T., Schiff, D., Tran, D.D., Ashby, L.S., Butowski, N.A., Iwamoto, F.M., Lindsay, R., Bullington, J., Schulder, M., Sherman, J., Goswami, T., & Reardon, D.A.
Poster Session: #2058 Central Nervous System Tumors
SL-701 with immunostimulants, alone and in combination with bev, was well-tolerated and demonstrated anti-tumor activity including multiple major responses. There is also ap reliminiarily promising survival tail in r/r GBM patients who received SL-701 with bev. Further analyses ongoing; updated data to be presented. (Read more)
Physician survey on utilization of clinical cancer genetics services at an academic institution
Kroll, D., Norman, M., McHenry, A., Stark, E., Johnson, K., Kaltman, R.D.
Publication Only: #e13507 Cancer Prevention, Hereditary Genetics, and Epidemiology
This study identified a gap between the cancer genetic services provided at an academic institution and the utilization of those services by its providers. Strategies for educating providers about the importance of cancer genetic counseling and implementing screening tools in the clinic to more easily identify potential candidates for GCT are needed. (Read more)
Disparities in health-related quality of life in women undergoing treatment for ovarian cancer: The role of individual-level and contextual social determinants
Moss, J., Murphy, J., Filiaci, V.L., Wenzel, L.B., Minasian, L.M., Temkin, S.M.
Publication Only: #e18628 Health Services Research, Clinical Informatics, and Quality of Care
Private health insurance was associated with improved HRQOL at the completion of treatment for advanced stage ovarian cancer. Implications of health insurance on HRQOL should be further investigated. (Read more)
High RDW as a predictive and prognostic factor in patients with diffuse large B-cell lymphoma treated with chemoimmunotheraphy
Paredes, S., Beltran, B.E., Sotomayor, E.M., Castillo, J.J., Salas, R.
Publication Only: #e19547 Hematologic Malignancies--Lymphoma and Chronic Lymphocytic Leukemia
High RDW appears to be an adverse predictor of response and survival in patients with de novo DLBCL treated with R-CHOP, independent of the IPI and NCCN-IPI scores. (Read more)
Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease
Kellner, J., Yvon, E., Khoury, J., Nguyen, T., Ramos, J., Olson, A.L., Nieto, Y., Ciurea, S.O., Nierkens, S., Delemarre, E., Jan Boelens, J., Champlin, R.E., Andersson, B., Parmar, S.
Publication Only: #e15047 Developmental Therapeutics--Immunotherapy
CB Tregs art dose level 10 e7/kg was well-tolerated with no infusional toxicity or impact on engraftment. While current dose level dod not prevent aGVHD regardless of fucosylation status of CB Tregs, chronic GVHD did not occur. High fevers observed in the fucosylated CB Treg recipients may be a result of expanding effector T cells and steroid treatment may have blunted Treg effect. Stage 2 of this clinical trial examining untreated CB Tregs at 1.0 e7/kg is currently underway. (Read more)
